222 related articles for article (PubMed ID: 23351358)
1. Cytostasis and morphological changes induced by mifepristone in human metastatic cancer cells involve cytoskeletal filamentous actin reorganization and impairment of cell adhesion dynamics.
Brandhagen BN; Tieszen CR; Ulmer TM; Tracy MS; Goyeneche AA; Telleria CM
BMC Cancer; 2013 Jan; 13():35. PubMed ID: 23351358
[TBL] [Abstract][Full Text] [Related]
2. Advanced assessment of migration and invasion of cancer cells in response to mifepristone therapy using double fluorescence cytochemical labeling.
Ritch SJ; Brandhagen BN; Goyeneche AA; Telleria CM
BMC Cancer; 2019 Apr; 19(1):376. PubMed ID: 31014286
[TBL] [Abstract][Full Text] [Related]
3. Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity.
Gamarra-Luques CD; Hapon MB; Goyeneche AA; Telleria CM
J Ovarian Res; 2014; 7():45. PubMed ID: 24795781
[TBL] [Abstract][Full Text] [Related]
4. Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression.
Tieszen CR; Goyeneche AA; Brandhagen BN; Ortbahn CT; Telleria CM
BMC Cancer; 2011 May; 11():207. PubMed ID: 21619605
[TBL] [Abstract][Full Text] [Related]
5. Abortifacient metapristone (RU486 derivative) interrupts CXCL12/CXCR4 axis for ovarian metastatic chemoprevention.
Zheng N; Chen J; Li T; Liu W; Liu J; Chen H; Wang J; Jia L
Mol Carcinog; 2017 Aug; 56(8):1896-1908. PubMed ID: 28277622
[TBL] [Abstract][Full Text] [Related]
6. The CT20 peptide causes detachment and death of metastatic breast cancer cells by promoting mitochondrial aggregation and cytoskeletal disruption.
Lee MW; Bassiouni R; Sparrow NA; Iketani A; Boohaker RJ; Moskowitz C; Vishnubhotla P; Khaled AS; Oyer J; Copik A; Fernandez-Valle C; Perez JM; Khaled AR
Cell Death Dis; 2014 May; 5(5):e1249. PubMed ID: 24853427
[TBL] [Abstract][Full Text] [Related]
7. Response of human ovarian carcinoma cell lines to antiprogestin mifepristone.
Rose FV; Barnea ER
Oncogene; 1996 Mar; 12(5):999-1003. PubMed ID: 8649817
[TBL] [Abstract][Full Text] [Related]
8. Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy.
Gamarra-Luques CD; Goyeneche AA; Hapon MB; Telleria CM
BMC Cancer; 2012 Jun; 12():200. PubMed ID: 22642877
[TBL] [Abstract][Full Text] [Related]
9. Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2.
Goyeneche AA; Seidel EE; Telleria CM
Invest New Drugs; 2012 Jun; 30(3):967-80. PubMed ID: 21424700
[TBL] [Abstract][Full Text] [Related]
10. [Induction of apoptosis by mifepristone in androgen-independent prostate cancer cell lines in vitro].
Zhang H; Lü JJ; Gao QZ; Zhang J
Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(6):382-5. PubMed ID: 16638347
[TBL] [Abstract][Full Text] [Related]
11. The metastatic capacity of high-grade serous ovarian cancer cells changes along disease progression: inhibition by mifepristone.
Ritch SJ; Noman ASM; Goyeneche AA; Telleria CM
Cancer Cell Int; 2022 Dec; 22(1):397. PubMed ID: 36494669
[TBL] [Abstract][Full Text] [Related]
12. Mifepristone inhibits GRβ coupled prostate cancer cell proliferation.
Ligr M; Li Y; Logan SK; Taneja S; Melamed J; Lepor H; Garabedian MJ; Lee P
J Urol; 2012 Sep; 188(3):981-8. PubMed ID: 22819113
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of mifepristone in the human LNCaP, LNCaP-C4, and LNCaP-C4-2 prostate cancer models in nude mice.
El Etreby MF; Liang Y; Johnson MH; Lewis RW
Prostate; 2000 Feb; 42(2):99-106. PubMed ID: 10617866
[TBL] [Abstract][Full Text] [Related]
14. Resensitization of breast cancer cells to anoikis by tropomyosin-1: role of Rho kinase-dependent cytoskeleton and adhesion.
Bharadwaj S; Thanawala R; Bon G; Falcioni R; Prasad GL
Oncogene; 2005 Dec; 24(56):8291-303. PubMed ID: 16170368
[TBL] [Abstract][Full Text] [Related]
15. Effects of mifepristone on invasive and metastatic potential of human gastric adenocarcinoma cell line MKN-45 in vitro and in vivo.
Li DQ; Wang ZB; Bai J; Zhao J; Wang Y; Hu K; Du YH
World J Gastroenterol; 2004 Jun; 10(12):1726-9. PubMed ID: 15188494
[TBL] [Abstract][Full Text] [Related]
16. Extracellular matrix 1 (ECM1) regulates the actin cytoskeletal architecture of aggressive breast cancer cells in part via S100A4 and Rho-family GTPases.
Gómez-Contreras P; Ramiro-Díaz JM; Sierra A; Stipp C; Domann FE; Weigel RJ; Lal G
Clin Exp Metastasis; 2017 Jan; 34(1):37-49. PubMed ID: 27770373
[TBL] [Abstract][Full Text] [Related]
17. Differential nuclear shape dynamics of invasive andnon-invasive breast cancer cells are associated with actin cytoskeleton organization and stability.
Chiotaki R; Polioudaki H; Theodoropoulos PA
Biochem Cell Biol; 2014 Aug; 92(4):287-95. PubMed ID: 25053513
[TBL] [Abstract][Full Text] [Related]
18. Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo.
Goyeneche AA; Carón RW; Telleria CM
Clin Cancer Res; 2007 Jun; 13(11):3370-9. PubMed ID: 17545545
[TBL] [Abstract][Full Text] [Related]
19. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells.
Gaddy VT; Barrett JT; Delk JN; Kallab AM; Porter AG; Schoenlein PV
Clin Cancer Res; 2004 Aug; 10(15):5215-25. PubMed ID: 15297425
[TBL] [Abstract][Full Text] [Related]
20. Heparanase-induced GEF-H1 signaling regulates the cytoskeletal dynamics of brain metastatic breast cancer cells.
Ridgway LD; Wetzel MD; Ngo JA; Erdreich-Epstein A; Marchetti D
Mol Cancer Res; 2012 Jun; 10(6):689-702. PubMed ID: 22513363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
